Form 4: LiPella Pharmaceuticals Director Acquires 25,000 Stock Options
SEC Form 4 Filing
Ryan Pruchnic, a director of LiPella Pharmaceuticals, acquired 25,000 stock options on March 15, 2024.
Summary
- On March 15, 2024, Ryan Pruchnic, a director at LiPella Pharmaceuticals Inc. (LIPO), acquired 25,000 stock options.
- The exercise price of these options is $0.77.
- The options are exercisable from March 15, 2024, and expire on March 15, 2034.
- Following the transaction, Pruchnic directly owns 25,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock option acquisition by a director, neither particularly positive nor negative on its own.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director can align their interests with those of shareholders, as the value of the options increases with the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of earliest transaction: Ryan Pruchnic acquired 25,000 stock options. |
| 03/15/2024 | Stock options become exercisable. |
| 03/15/2034 | Expiration date of the stock options. |
| 03/19/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, LIPO, LiPella Pharmaceuticals, insider trading, Ryan Pruchnic, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.